Human Trials

Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion

Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), announced the initiation of its Phase 2a study with GB-102 in patients with macular edema (ME) secondary to DME or RVO.

Novartis’ Cosentyx meets primary endpoint at Week 16 in PREVENT trial

Novartis said that the phase 3 trial of its psoriasis drug Cosentyx (secukinumab), called PREVENT, in patients with non-radiographic axial spondyloarthritis (nr-axSpA), has met its primary endpoint at Week 16.

Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata

Concert Pharmaceuticals announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.

Poxel initiates phase 1b multiple ascending dose trial for NASH drug candidate

POXEL, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the initiation of a Phase 1b double-blind, randomized, placebo-controlled study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics (PK) as well as support dose selection for a pivotal study of PXL065.

Alnylam initiates APOLLO-B phase 3 study of patisiran for treatment of transthyretin amyloidosis with cardiomyopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.

Arrowhead presents initial top-line clinical data and preclinical data on RNAi candidates ARO-APOC3 and ARO-ANG3

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE

Novartis’ RMS drug ofatumumab achieves primary endpoints in phase III studies

Novartis’ ofatumumab (OMB157) has achieved the primary endpoints in two phase III trials of relapsing multiple sclerosis (MS).

Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

Celgene Corporation has announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.

VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma

VBI Vaccines has announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system.